Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for ...

Jaguar Health’s (JAGX) Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget ...

In ONTARGET patients, glomerular filtration rate (GFR) decline averaged 0.9 ml/min per year, which is within the physiologic range of GFR loss (0.6–1.1 ml/min per year) observed in healthy ...

with additional POC IIT results expected throughout 2025 FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the ...

Research and Development: The R&D expense decreased by $2.1 million, from $18.6 million for the year ended December 31, 2023 compared to $16.5 million in 2024, primarily due to the conclusion of the ...

The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to ...

All antihypertensive drugs lower (by definition) BP, and the main benefit based on a large number of randomized trials is due to lowering of BP per se and is largely independent of the drugs employed.

Future’s Best of Show at NAB 2025 awards have been announced. The annual awards celebrate products being launched or on display at the NAB Show 2025 in Las Vegas.